Sensitive and selective liquid chromatography-electrospray ionization mass spectrometry analysis of ginkgolide B in dog plasma

被引:19
作者
Lv, H [1 ]
Wang, GJ [1 ]
Li, H [1 ]
Huang, MW [1 ]
Xie, HT [1 ]
Huang, CR [1 ]
Sun, JG [1 ]
Lv, T [1 ]
机构
[1] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing 210009, Peoples R China
关键词
ginkgolide B; LC-ESI-MS; pharmacokinetics;
D O I
10.1016/j.jpba.2005.06.004
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
As an important active constituent of Ginkgo biloba extract, ginkoglide B is a highly selective and competitive PAF receptor antagonist which has been widely used in clinical applications. A novel high-performance liquid chromatography-electrospray ionization mass spectromentry (LC-ESI-MS) method was developed for the determination of ginkgolide B in dog plasma. After liquid/liquid extraction with ether and high-performance liquid chromatography (HPLC) gradient separation with 0.01% of ammonia water (v/v)-methanol as the mobile phase, the deprotonized anions [M-H](-1) at m/z 423 of ginkoglide 13, and [M-H](-1) at m/z 492 of internal standard (IS) glibenclamide were analyzed by LC-ESI-MS in selected ion monitoring (SIM) mode. Chromatographic separation was achieved in less than 9 min and calibration curve was linear over a concentration range of 0.1-20 ng/ml. The described assay method was successfully applied to the pre-clinical pharmacokinetic study of ginkoglide B. After intragastric administration of ginkgolide B to beagle dogs, C-max and T-max of ginkgolide B were 43.8 +/- 6.24 ng/ml and 0.5 h, respectively, and the elimination half-life (t(1/2)) was 2.85 +/- 0.54 h. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:88 / 94
页数:7
相关论文
共 10 条
[1]   Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS [J].
Biber, A ;
Koch, E .
PLANTA MEDICA, 1999, 65 (02) :192-193
[2]  
BRAQUET P, 1987, Drugs of the Future, V12, P643
[3]  
HOSFORD DJ, 1990, METHOD ENZYMOL, V187, P433
[4]   Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia [J].
Kanowski, S ;
Herrmann, WM ;
Stephan, K ;
Wierich, W ;
Horr, R .
PHARMACOPSYCHIATRY, 1996, 29 (02) :47-56
[5]   A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia [J].
LeBars, PL ;
Katz, MM ;
Berman, N ;
Itil, TM ;
Freedman, AM ;
Schatzberg, AF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (16) :1327-1332
[6]   The bioavailability of ginkgolides in Ginkgo biloba extracts [J].
Li, CL ;
Wong, YY .
PLANTA MEDICA, 1997, 63 (06) :563-565
[7]   The CNS effects of Ginkgo biloba extracts and ginkgolide B [J].
Maclennan, KM ;
Darlington, CL ;
Smith, PE .
PROGRESS IN NEUROBIOLOGY, 2002, 67 (03) :235-257
[8]   Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts [J].
Mauri, P ;
Simonetti, P ;
Gardana, C ;
Minoggio, M ;
Morazzoni, P ;
Bombardelli, E ;
Pietta, P .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2001, 15 (12) :929-934
[9]   Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of terpene lactones in plasma of animals [J].
Mauri, P ;
Minoggio, M ;
Iemoli, L ;
Rossoni, G ;
Morazzoni, P ;
Bombardelli, E ;
Pietta, P .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 32 (4-5) :633-639
[10]  
Yang F.Y., 2001, CHIN PHARM J, V36, P616